Clinical Trials in Indiana

Browse 99 Indiana Medical Studies Across 942 Cities
48 Phase 3 Trial · 4789 Indiana Clinics

Display Results

AllMost EffectiveMost SafeSenior FriendlyPediatricNo Placebo

Clinical Trials Clinical Trials in Indiana

Reviewed by Michael Gill, B. Sc.

Image of Alliance for Multispecialty Research, LLC ( Site 0093) in Daphne, United States.

10 Indiana Clinical Trials Near Me

Top Cities for Indiana Clinical Trials

Anchorage

76Active Trials

Providence Alaska Medical CenterTop Active Site

New York

71Active Trials

Memorial Sloan Kettering Cancer CenterTop Active Site

Indiana Clinical Trials by Phase of Trial

N/A Indiana Clinical Trials

17Active Indiana Clinical Trials

17Number of Unique Treatments

487Number of Active Locations

ACURATE neo2™ Transfemoral TAVR System Patients Boston Scientific WaveWriter SCS System Buspirone Participants with history of ASCVD DECAD decision aid Pharmacogenetic testing Patient-Caregiver Dyads Bilateral Salpingectomy Macrodyne LivMD plate Microport Firehawk stent Exercise Hemodialysis Practicing the Opposite (PTO)HIVD+/R+Pembrolizumab iFuse 3-D in Bedrock Configuration

Most Recent Indiana Clinical Trials

Clinical Trial

Began Recruiting Date

Phase

IMG-007 Dose 1 for Alopecia Areata

9/1/2023

Phase 1 & 2

MK-0616 for High Cholesterol

8/10/2023

Phase 3

MK-0616 for High Cholesterol

8/8/2023

Phase 3

FP-001 42 mg for Puberty

6/2/2023

Phase 3

Ziltivekimab 15 mg for Heart Failure

5/8/2023

Phase 3

About The Author

Michael Gill - B. Sc.

First Published: October 28th, 2021

Last Reviewed: September 15th, 2023

References¹ Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14. Review. https://pubmed.ncbi.nlm.nih.gov/31401903² Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14. https://pubmed.ncbi.nlm.nih.gov/31401903³ Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, Egeberg A, Valdez H, Zhang M, Farooqui SA, Romero W, Thorpe AJ, Rojo R, Johnson S. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. Am J Clin Dermatol. 2021 Sep;22(5):693-707. doi: 10.1007/s40257-021-00618-3. Epub 2021 Aug 18. https://pubmed.ncbi.nlm.nih.gov/34406619⁴ Remon J, Girard N, Novello S, de Castro J, Bigay-Game L, Bernabé R, Greillier L, Mosquera J, Cousin S, Juan O, Sampayo M, Besse B. PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. Clin Lung Cancer. 2022 May;23(3):e243-e246. doi: 10.1016/j.cllc.2021.07.008. Epub 2021 Jul 20. https://pubmed.ncbi.nlm.nih.gov/34393061⁵ Remon J, Girard N, Novello S, de Castro J, Bigay-Game L, Bernabe R, Greillier L, Mosquera J, Cousin S, Juan O, Sampayo M, Besse B. PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. Clin Lung Cancer. 2022 May;23(3):e243-e246. doi: 10.1016/j.cllc.2021.07.008. Epub 2021 Jul 20. https://pubmed.ncbi.nlm.nih.gov/34393061⁶ Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, Egeberg A, Valdez H, Zhang M, Farooqui SA, Romero W, Thorpe AJ, Rojo R, Johnson S. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. Am J Clin Dermatol. 2021 Sep;22(5):693-707. doi: 10.1007/s40257-021-00618-3. Epub 2021 Aug 18. Erratum in: Am J Clin Dermatol. 2021 Nov;22(6):905. https://pubmed.ncbi.nlm.nih.gov/34406619⁷ Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, Egeberg A, Valdez H, Zhang M, Farooqui SA, Romero W, Thorpe AJ, Rojo R, Johnson S. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. Am J Clin Dermatol. 2021 Sep;22(5):693-707. doi: 10.1007/s40257-021-00618-3. Epub 2021 Aug 18. Erratum in: Am J Clin Dermatol. 2021 Oct 13;:. https://pubmed.ncbi.nlm.nih.gov/34406619⁸ Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, Egeberg A, Valdez H, Zhang M, Farooqui SA, Romero W, Thorpe AJ, Rojo R, Johnson S. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. Am J Clin Dermatol. 2021 Sep;22(5):693-707. doi: 10.1007/s40257-021-00618-3. Epub 2021 Aug 18. Erratum In: Am J Clin Dermatol. 2021 Nov;22(6):905. https://pubmed.ncbi.nlm.nih.gov/34406619⁹ Ditsch N, Rubio IT, Gasparri ML, de Boniface J, Kuehn T. Breast and axillary surgery in malignant breast disease: a review focused on literature of 2018 and 2019. Curr Opin Obstet Gynecol. 2020 Feb;32(1):91-99. doi: 10.1097/GCO.0000000000000593. https://pubmed.ncbi.nlm.nih.gov/31833973¹⁰ Feagan BG, Schreiber S, Afzali A, Rieder F, Hyams J, Kollengode K, Pearlman J, Son V, Marta C, Wolf DC, D'Haens GG. Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program. Contemp Clin Trials. 2022 Nov;122:106958. doi: 10.1016/j.cct.2022.106958. Epub 2022 Oct 5. https://pubmed.ncbi.nlm.nih.gov/36208720